BAKER BROS. ADVISORS LP Q3 2017 Filing
Filed November 14, 2017
Portfolio Value
$12.3B
Holdings
121
Report Date
Q3 2017
Filing Type
13F-HR
All Holdings (121 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Immune Design Corp. | 148,937 | $1.5B | 12.50% | |
| 102 | —Sunesis Pharmaceuticals, Inc. | 741,665 | $1.4B | 11.67% | |
| 103 | CLLSCellectis S.A. | 50,000 | $1.4B | 11.54% | |
| 104 | —MediWound Ltd. | 226,000 | $1.2B | 9.80% | |
| 105 | I9DNArbutus Biopharma Corporation | 180,582 | $1.1B | 9.08% | |
| 106 | —Ritter Pharmaceuticals, Inc. | 2,800,000 | $980.0M | 7.95% | |
| 107 | —Affimed N.V. | 400,000 | $900.0M | 7.30% | |
| 108 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $819.0M | 6.64% | |
| 109 | —Five Prime Therapeutics, Inc. | 19,247 | $787.0M | 6.38% | |
| 110 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $772.0M | 6.26% | |
| 111 | —BioDelivery Sciences International, Inc. | 210,021 | $620.0M | 5.03% | |
| 112 | FLGTFulgent Genetics, Inc. | 125,000 | $599.0M | 4.86% | |
| 113 | —Proteon Therapeutics, Inc. | 298,591 | $597.0M | 4.84% | |
| 114 | —InVivo Therapeutics Holdings Corp. | 400,000 | $580.0M | 4.70% | |
| 115 | —Molecular Templates, Inc. | 72,412 | $505.0M | 4.10% | |
| 116 | —T2 Biosystems, Inc. | 100,000 | $420.0M | 3.41% | |
| 117 | CCXIEURChemoCentryx, Inc. | 49,064 | $364.0M | 2.95% | |
| 118 | —BioPharmX Corporation | 598,758 | $171.0M | 1.39% | |
| 119 | —Tenax Therapeutics, Inc. | 348,374 | $126.0M | 1.02% | |
| 120 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $98.0M | 0.79% | |
| 121 | —BioTime, Inc. | 20,084 | $4.0M | 0.03% |
PreviousPage 2 of 2